This protocol addresses foot osteoarthritis and outlines an oral pharmacological approach. The use of duloxetine in osteoarthritis management has been evaluated across major clinical guidelines, and its place in therapy reflects ongoing assessment of evidence and tolerability.
The protocol involves oral duloxetine. The full protocol specifies how this agent fits within the clinical decision framework — including the conditions under which it is considered and the grading of supporting evidence.
DOI: 10.1016/j.rdc.2022.03.009.
Though duloxetine is approved for OA in some countries, there were only conditional or weak recommendations for its use across all guidelines, reflecting general concerns about efficacy and tolerability.